Cantor Fitzgerald Increases Earnings Estimates for Arvinas

Arvinas, Inc. (NASDAQ:ARVN) – Investment analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report released on Thursday, November 6th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($0.46) for the year, up from their previous estimate of ($1.12). The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Cantor Fitzgerald also issued estimates for Arvinas’ FY2026 earnings at ($2.48) EPS.

ARVN has been the subject of several other reports. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 target price on shares of Arvinas in a report on Tuesday, October 7th. HC Wainwright cut their price objective on shares of Arvinas from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Arvinas in a research report on Wednesday, October 8th. The Goldman Sachs Group restated a “sell” rating and set a $6.00 target price (down from $8.00) on shares of Arvinas in a research report on Wednesday, October 15th. Finally, Bank of America lowered Arvinas from a “buy” rating to a “neutral” rating and set a $10.00 price target for the company. in a research note on Wednesday, September 24th. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $16.39.

Arvinas Trading Up 0.2%

Shares of NASDAQ:ARVN opened at $11.21 on Monday. Arvinas has a 12-month low of $5.90 and a 12-month high of $27.76. The business has a 50 day moving average of $8.96 and a two-hundred day moving average of $7.93. The company has a market capitalization of $719.91 million, a PE ratio of -13.84 and a beta of 2.38.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.27. The firm had revenue of $41.90 million for the quarter, compared to the consensus estimate of $29.36 million. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The company’s revenue was down 59.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.68) earnings per share.

Institutional Investors Weigh In On Arvinas

Large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd lifted its position in shares of Arvinas by 965.4% in the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock valued at $33,000 after acquiring an additional 4,219 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after purchasing an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after purchasing an additional 3,500 shares in the last quarter. CWM LLC boosted its stake in Arvinas by 2,317.5% during the 1st quarter. CWM LLC now owns 7,615 shares of the company’s stock worth $53,000 after purchasing an additional 7,300 shares during the last quarter. Finally, State of Wyoming purchased a new stake in shares of Arvinas during the third quarter worth $68,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Arvinas

In related news, Director Briggs Morrison purchased 30,000 shares of Arvinas stock in a transaction that occurred on Monday, September 22nd. The stock was purchased at an average price of $7.57 per share, for a total transaction of $227,100.00. Following the transaction, the director directly owned 76,021 shares in the company, valued at approximately $575,478.97. This trade represents a 65.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 4.73% of the stock is currently owned by company insiders.

Arvinas announced that its Board of Directors has approved a share buyback plan on Wednesday, September 17th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the company to repurchase up to 17.9% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.